Asiatic Laboratories (DHA:ASIATICLAB) Debt-to-Revenue : 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ASIATICLAB Asiatic Laboratories Ltd DHA:ASIATICLAB
32 GF Score
Price BDT105.20
! 1 Warning Sign
View Full Analysis

What is Asiatic Laboratories Debt-to-Revenue?

Asiatic Laboratories DHA:ASIATICLAB +2.83% 32 Debt-to-Revenue is 0.00 as of . 20. GuruFocus rates DHA:ASIATICLAB with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Debt-to-Revenue measures a company's ability to pay off its debt.

Asiatic Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was BDT0.00 Mil. Asiatic Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was BDT0.00 Mil. Asiatic Laboratories's annualized Revenue for the quarter that ended in . 20 was BDT0.00 Mil.

Asiatic Laboratories Debt-to-Revenue Historical Data

* Premium members only.

The historical data trend for Asiatic Laboratories's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Asiatic Laboratories Debt-to-Revenue Chart

Asiatic Laboratories Annual Data
Trend
Debt-to-Revenue

Asiatic Laboratories Semi-Annual Data
Debt-to-Revenue

DHA:ASIATICLAB vs ZTS, UTHR, VTRS: Debt-to-Revenue Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Asiatic Laboratories's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Asiatic Laboratories Debt-to-Revenue vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Asiatic Laboratories's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Asiatic Laboratories's Debt-to-Revenue falls into.


DHA:ASIATICLAB
32GF Score
Asiatic Laboratories Ltd DHA:ASIATICLAB
Debt-to-Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Asiatic Laboratories Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Asiatic Laboratories's Debt-to-Revenue for the fiscal year that ended in . 20 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=( + ) / N/A
=N/A

Asiatic Laboratories's annualized Debt-to-Revenue for the quarter that ended in . 20 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=( + ) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is one times the quarterly (. 20) Revenue data.

Frequently Asked Questions Learn more about Debt-to-Revenue →
What does a Debt-to-Revenue of 0.00 mean?
Asiatic Laboratories (DHA:ASIATICLAB) has a Debt-to-Revenue of 0.00 as of . 20.
Is Asiatic Laboratories' Debt-to-Revenue too high?
Asiatic Laboratories' current Debt-to-Revenue is 0.00. Overall, Asiatic Laboratories has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Asiatic Laboratories' Debt-to-Revenue compare to ZTS and UTHR?
Asiatic Laboratories' Debt-to-Revenue of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Revenue for a Drug Manufacturers company?
A good Debt-to-Revenue depends on the Drug Manufacturers industry context. However, Debt-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Revenue mean?
A high Debt-to-Revenue can signal that a stock is expensive relative to its fundamentals. Asiatic Laboratories's current Debt-to-Revenue is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asiatic Laboratories stock overvalued right now?
Asiatic Laboratories (DHA:ASIATICLAB) has a current Debt-to-Revenue of 0.00. The current Debt-to-Revenue is 0.00. Asiatic Laboratories' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Revenue calculated?
Debt-to-Revenue is calculated from a company's financial statements. For Asiatic Laboratories (DHA:ASIATICLAB), the current Debt-to-Revenue is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Asiatic Laboratories Business Description

Address Siddeshwari Circular Road, 42-43, Treasure Island (5 th Floor) Shantinagar, Dhaka, BGD, 1217
Asiatic Laboratories Ltd is engaged in manufacturing and marketing of a wide range of the rapeutical medicines pharmaceutical products in the categories of Biological, Non-Biological & Sterile Pharmaceutical dosage. It has 80 generic molecules comprising therapeutic classes like antibiotics, antihistamines, bronchodilators, vitamins-minerals, antiulcerants, laxatives, gastroprokinetics, antihematinic, anthelmentics, CNS drugs, respiratory drugs, NSAIDs, dermatological preparations and sterile ophthalmic preparations.
32GF Score

Get the complete analysis for DHA:ASIATICLAB

Debt-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT105.20
Price